Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to find the best dose of EVM14 when used alone or with pembrolizumab in people with solid tumors. The people in this study have a solid tumor that keeps growing after treatment and has spread. This study includes people with:
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called metastatic castration-resistant prostate cancers (mCRPC).
Researchers are finding the best dose of MB-CART19.1 immunotherapy in people with lymphoma. The people in this study have central nervous system lymphoma (CNSL) that came back or keeps growing after treatment.
This study is assessing the safety and effectiveness of ASTX727 in people who have malignant peripheral nerve sheath tumors (MPNST) with a mutation in a gene complex called PRC2 (EED or SUZ12). ASTX727 is a combination of two drugs (cedazuridine and decitabine) that have been designed to target cancer cells with a PRC2 complex genetic mutation and disrupt the cells' ability to survive and grow.
Researchers want to find the best dose of TORL-1-23 to use in people with advanced solid tumors. The people in this study have solid tumors that have spread and cannot be successfully treated with standard therapies.
Researchers want to find the best dose of JNJ-88549968 to use in people with myeloproliferative neoplasms. Examples of these cancers include myelofibrosis and essential thrombocythemia. In addition, their cancers have a change (mutation) in the CALR gene.
Researchers want to find the highest dose of ERAS-0015 that can be given safely in people with advanced solid tumors. The people in this study have cancer that has metastasized (spread) and has a mutation in the RAS gene.
Researchers are comparing two combination treatments for breast cancer that has metastasized (spread) or is inoperable (cannot be removed surgically). The people in this study have breast cancer that has hormone receptors (HR) but is negative for the HER2 protein.
Researchers in this study want to find the best dose of STAR0602 to use in people with advanced solid tumors. The people in this study have cancer that is inoperable (cannot be taken out with surgery) or metastatic (has spread). STAR0602 boosts the immune system to stop tumor growth. It is given intravenously (by vein).
Researchers want to see if removing only 1 lymph node with cancer prevents melanoma from coming back in that area. The people in this study have melanoma that spread to just 1 lymph node.
